CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients

Antiphospholipid Antibody Syndrome Clinical Trial

Official title: Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome

Status Completed

Clinical Trial Summary

The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.

Clinical Trial Description

Antiphospholipid Antibody Syndrome (APL) is an autoimmune disease that increases ones risk for blood clots. Therefore, these patients receive anticoagulation therapy with warfarin. Point of care devices such as the CoaguChek XS are often used to monitor International Normalized Ratio (INR) in patients on warfarin. However, the antibodies present in patients with APL may lead to false INR results when using the CoaguChek XS. This study will compare the accuracy of the CoaguChek XS in measuring INR in patients with APL by measuring INR by the CoaguChek XS and a standard lab as a reference point. Patients on warfarin for indications other than APL will be measured by both methods as well to serve as a control group. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Antiphospholipid Antibody Syndrome
• Antiphospholipid Syndrome
• Syndrome

• NCT number: NCT02139072
• Study type: Observational
• Source: University of Florida
• Status: Completed
• Phase: N/A
• Start date: March 2015
• Completion date: January 2016